JM
John S. Montalbano
Director

John S. Montalbano insider trades: AbCellera Biologics (ABCL) stock purchases

Director, AbCellera Biologics Last trade Aug 18, 2026 14 Form 4 filings
$0
Sold, last 12 months
0 sales
$289K
Bought, last 12 months
2 buys
10
Open-market trades
since 2020
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where John reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 18, 2026ABCL↑ Buy$110K
Nov 26, 2025ABCL↑ Buy$178K
Mar 10, 2025ABCL↑ Buy$57K
Mar 6, 2025ABCL↑ Buy$141K
Nov 8, 2023ABCL↑ Buy$137K
Mar 4, 2022ABCL↑ Buy$85K
Mar 1, 2022ABCL↑ Buy$181K
Aug 16, 2021ABCL↑ Buy$103K
Dec 15, 2020ABCL↑ Buy$400K
Dec 15, 2020ABCL↑ Buy$100K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ABCL insiders

Open-market trades in the last 12 months

About John S. Montalbano's insider trades

John S. Montalbano is a director at AbCellera Biologics (ABCL). Since Dec 15, 2020, John has reported 10 open-market purchases worth $1.5M and no sales on SEC Form 4. In the last 12 months: 2 buys ($289K).

Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABCL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.